|
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Syzygium cumini extract was more efficient than B. forficata in reducing hyperglycaemia, redox disturbances and the changes in mRNA expression of insulin receptor.
|
28267671 |
2017 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that multiple cave populations carry a mutation in the insulin receptor that leads to decreased insulin binding in vitro and contributes to hyperglycaemia.
|
29562229 |
2018 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Individuals with only one allele for a functional insulin receptor have a tendency to hyperinsulinaemia but not to hyperglycaemia.
|
2687060 |
1989 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Together, the data suggest that the regulatory serine or threonine phosphorylation site(s) involved in the inhibitory effect of hyperglycemia are neither located in the C-terminus nor in the juxtamembrane region of the insulin receptor beta subunit.
|
7867639 |
1995 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that mice with deletion of the insulin receptor alone showed not only hyperglycemia but also a 70% decrease in plasma insulin-like growth factor 1 and delayed growth during the first 2 months of life, a 24-fold increase in the soluble leptin receptor and a 19-fold increase in plasma leptin levels.
|
29300910 |
2018 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previously we demonstrated that NEU1 activates the insulin receptor (IR) and that NEU1-deficient CathA<sup>S190A-Neo</sup> mice (hypomorph of the NEU1 activator protein, cathepsin A/CathA) on a high-fat diet (HFD) develop hyperglycaemia and insulin resistance faster than wild-type animals.
|
29735266 |
2018 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Leptin treatment has shown some success in treating hyperglycemia in patients with insulin receptor gene mutations.
|
23047930 |
2013 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Donohue syndrome ([DS]; leprechaunism) describes a genetic autosomal recessive disorder that results from the presence of homozygous or compound heterozygous mutations in the insulin receptor gene (INSR; 19p13.3-p13.2).Donohue syndrome is associated with a fatal congenital form of dwarfism with features of intrauterine and postnatal growth retardation, exaggerated hyperglycemia with hyperinsulinism and dysmorphic abnormalities.We present a case of DS owing to the rarity of this syndrome (1 case in every million births).
|
26871809 |
2016 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oral HP<i>β</i>CD/Ang-(1-7) treatment decreased <i>ACE</i> and <i>AT1R</i>, increased <i>ACE2</i> gene expression in the liver, and restored thiobarbituric acid reactive substances (TBARS), catalase (CAT), superoxide dismutase (SOD), insulin receptor substrate (<i>Irs-1</i>), glucose transporter type 4 (<i>GLUT4</i>), and serine/threonine kinase 2 (<i>AKT-2</i>) gene expression in the liver and gastrocnemius muscle improving hepatic function, cholesterol levels, and hyperglycemia in MetS rats.
|
31396301 |
2019 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Homozygous or compound heterozygous mutations within the insulin binding domain of the human insulin receptor (INSR) are usually associated with severe impairment of insulin binding leading to Donohue syndrome ("Leprechaunism"), which is characterized by excessive hyperglycemia with hyperinsulinism, pre- and postnatal growth retardation, distinct dysmorphism and early death.
|
18411068 |
2008 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Acute induction of insulin receptor knockout in adipocytes changed the substrate preference to fat before induction of a diabetic phenotype including hyperinsulinaemia and hyperglycaemia.
|
31309261 |
2019 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia.
|
16278247 |
2006 |
|
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The expression of the insulin receptor (IR) signaling cascade, including IR, IR substrate, phosphatidylinositol 3-kinase, Akt, and glucose transporter 4, was inhibited both in the skeletal muscle and the liver, which might be a main reason for the hyperglycemia and hyperinsulinemia.
|
28397090 |
2017 |
|
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Diet-induced obesity (DIO) in mice developed hyperglycemia and insulin resistance, accompanying with a reduction of insulin receptor (INSR) expression.
|
26179126 |
2015 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the Met-985 insulin-receptor variant associates with hyperglycemia and represents a risk factor for NIDDM.
|
8900242 |
1996 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We tested the hypothesis that impaired insulin receptor signaling in myocytes worsens cardiac remodeling and function following injury, even in the absence of hyperglycemia.
|
16216265 |
2005 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin.
|
11887975 |
2001 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Humans with congenital absence of the islets of Langerhans and mice rendered null for the insulin receptor rapidly develop severe hyperglycemia and ketoacidosis and, if untreated, die in the early neonatal period.
|
11443207 |
2001 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Insulin receptor (IR) insufficiency in β-cells leads to impaired insulin secretion and reduced β-cell hyperplasia in response to hyperglycemia.
|
29029025 |
2018 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, her endogenous immunoreactive insulin showed reduced biologic activity during a glucose-clamp study with hyperglycemia and a reduced ability to bind to the insulin receptor and stimulate glucose transport in vitro.
|
6371526 |
1984 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dose-limiting hyperglycemia has been observed for other IGF1R/INSR inhibitors in clinical trials.
|
28243682 |
2017 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Non-peptidyl small molecule, adenosine, 5'-Se-methyl-5'-seleno-, 2',3'-diacetate, activates insulin receptor and attenuates hyperglycemia in type 2 diabetic Lepr<sup>db/db</sup> mice.
|
31378829 |
2019 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Whether leflunomide can control hyperglycemia and sensitize the insulin receptor has not been tested.
|
29496905 |
2018 |
|
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We investigated two potential mechanisms that might be relevant for the abnormal function of the insulin receptor in NIDDM, i.e. changes in the expression of the receptor isoforms and the effect of hyperglycaemia on insulin receptor tyrosine kinase activity.
|
7821730 |
1994 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Type B insulin resistance (IR) is a rare autoimmune disease characterized by the presence of insulin receptor autoantibodies, resulting in a marked IR inducing hyperglycemia.
|
28262212 |
2017 |